March 27, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 27, 2026

In the S&P 500 Healthcare stream, biotech filings dominate with widespread cost discipline driving net loss narrowing averaging 42% YoY across Werewolf Therapeutics (-14% to $60.8M), Kezar Life Sciences (-33% to $56M), Humacyte (-73% to $40.8M), and Alamar Biosciences (-37% to $29.8M), fueled by R&D cuts of 20-49% and G&A reductions of 17-21%. Revenue acceleration shines in diagnostics and providers: Alamar +195% YoY to $74.2M, IDEXX Laboratories +10% with EPS +23% to $13.08, Elevance Health +13% to $197.6B. Clinical catalyst from Kodiak Sciences' Phase 3 superiority in diabetic retinopathy offsets patent reaffirmation favoring Broad Institute at Editas Medicine. Cash runways vary, with Werewolf limited to Q4 2026 prompting strategic review incl. sale/merger. Mature firms prioritize returns (Elevance $4.1B repurchases/dividends) amid proxy season recaps. Portfolio implications: Biotech turnaround via op ex efficiency supports overweight on revenue-generating names like IDEXX/Humacyte; monitor IPOs, trials, and May AGMs for catalysts amid mixed sentiment (positive in 4/9 key health filings).

32 high priority18 medium50 total filings

March 26, 2026·daily

S&P 500 Technology Sector SEC Filings — March 26, 2026

Across 13 filings from the S&P 500 Technology stream (with some cross-sector inclusions), dominant themes include neutral proxy statements for upcoming AGMs, mixed financial results highlighting cost discipline amid revenue softness, and selective growth in reserves/operations. Period-over-period trends show revenue declines averaging -5% YoY in reporting companies (e.g., Arcadia -4% FY2025, Q4 -26%), offset by operating expense cuts (Arcadia -15% FY, Mueller +24.4% op income YoY), with outliers like Mueller's record +10.9% sales and +26.5% net income. Critical developments: Mueller's 2030 plan targeting $1.5B op income, Arcadia's terminated deal and $2.1M cash infusion for growth, AParadise SPAC progress toward ENHA NYSE listing, and Canadian Natural's +4.5% proved reserves to 15,910 MMBOE. No insider trading activity reported across filings, limiting conviction signals; capital allocation shines with Mueller's $244M buybacks and 25% dividend hike. Portfolio implications: Tech exposure limited to stable Apple passive stake; monitor governance votes and May catalysts for alpha in industrials/biosciences proxies. Overall, cautious optimism from improving losses (+31-46% YoY in Arcadia) and strategic plans amid cash pressures.

7 high priority6 medium13 total filings

March 26, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 26, 2026

Across 24 NASDAQ-100 related SEC filings from March 26, 2026, overarching themes include cost discipline driving narrower losses in biotech/agrotech (Arcadia Biosciences FY loss improved 31% YoY to $2.3M, MetaVia net loss down 53% to $13M), robust industrial performance (CMC Q2 FY26 EBITDA +114% YoY to $297.5M, Mueller 2025 net income +26.5% YoY to $765M), and financing for growth (Keurig $5.55B notes for JDE Peet’s acquisition, Arcadia $2.1M proceeds). Period-over-period trends show mixed revenues (4/10 with declines avg -15% YoY, e.g., Arcadia -4% FY), but operating expenses down avg 25% YoY across reporting firms, boosting margins in winners like CMC (+610 bps to 14%). Resource firms added reserves (Canadian Natural +4.5% to 15,910 MMBOE via acquisitions), while proxies signal governance evolution (Murphy USA declassification). Neutral 13G amendments from Vanguard indicate passive shifts without ownership changes. Critical implications: Industrials offer strength amid sector rotation, biotechs present turnaround plays with cash runways into late 2026, but leverage risks loom in deals like Keurig's.

11 high priority13 medium24 total filings

March 26, 2026·daily

S&P 500 Financials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (primarily banks, insurers, REITs, asset managers amid broader microcap/SPAC noise), sentiment skews mixed/neutral (32/50 filings), with 12 companies reporting YoY revenue growth averaging +13% (e.g., Lumexa +7.8%, Leef Brands +22.1%) offset by 11 declines averaging -28% (e.g., CaliberCos -60.7%, STRATA -9%). Net losses narrowed in 9 firms (avg improvement 35%) but widened in 8 (avg +18%), highlighting persistent profitability challenges despite asset growth in credit investors (MSD +40.7%, AB Private +16.9%). SPAC/de-SPAC and M&A activity dominates (18 filings), signaling Q2 2026 catalysts with $500M+ proceeds (e.g., Xanadu, Suncrete). Capital allocation leans conservative: dividends in REITs (BlackRock $0.96/share), buybacks/dividends in retail proxies (Williams Sonoma $862M buybacks + $327M divs), no major cuts. Forward-looking guidance stable (Lumexa reiterates 2026 rev $1.045-1.097B), but risks from delistings (FiscalNote), going concerns (Indigo SPAC), and leverage rises. Portfolio implications: Bullish on SPAC mergers and credit growth; bearish on revenue-dependent microcaps; watch NIM/ROE trends in banks/insurers for rate sensitivity.

37 high priority13 medium50 total filings

March 26, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via trusts and adjacents), proxy statements dominate (e.g., ADM, Newell, Philip Morris, Oshkosh) signaling peak governance season with May 2026 AGMs, board recommendations FOR comp plans/auditors amid neutral sentiment. Period-over-period trends show mixed revenue growth (e.g., Insight Molecular +116% YoY, Interlink +1.8% YoY, Worthington Steel +12% Q3 YoY) offset by widespread margin compression (Interlink gross -270bps YoY, Rockwell Q4 flat at 21% but FY sales -32% YoY) and cash deteriorations (Eltek ops cash -75% YoY to $1.1M, Rockwell ops cash used $659k vs provided $4.2M prior). Capital allocation leans shareholder-friendly in outliers (Oshkosh dividend +11.8% to $0.57, cash returned +73% YoY) but debt-heavy for M&A (Keurig €3B+$2.55B notes for JDE Peet’s). Forward-looking catalysts cluster in FDA reviews (Insight Q3 2026), acquisitions (Keurig by Feb 2027), and AGMs, with bullish alpha in diagnostics/health adjacents but bearish pressures from macro risks (Kornit inflation/overcapacity). Portfolio-level: 12/50 filings show revenue growth >10% YoY, but 8/20 with margin data average -150bps compression; staples-specific neutral on governance, mixed on financing.

29 high priority21 medium50 total filings

March 26, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 26, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like materials and construction amid sparse pure industrials), proxy season dominates with 15+ DEF/DEFA14A filings scheduling May 2026 annual meetings, signaling routine governance amid neutral-to-positive sentiment on board refreshes and comp approvals. FY2025 financials reveal mixed trends: revenue growth in select names like Paychex (+19.8% YoY Q3) and Iridex (+8% FY), but widespread loss widening in biotechs (e.g., Acumen +19%, Upstream +128%) and margin pressures (e.g., Evogene gross loss from inventory impairment); banks show NIM expansion (Farmers & Merchants +34 bps to 3.02%) offset by deposit declines (-5%). Capital returns shine with Newmont's $1.1B dividends/$3B buybacks and Banc of California's 8% share repurchase, while forward catalysts cluster in Q2 2026 (Rhythm EMA approval, multiple AGMs). Portfolio-level patterns include cost discipline (R&D/G&A cuts in 7/12 10-Ks averaging -25% YoY) amid cash burn, biotech regulatory tailwinds, and M&A like Corebridge-Equitable all-stock deal for $1.5T AUM scale. Implications: tactical buys in outperforming industrials like GE (passive Vanguard stake) and Newmont, caution on biotech cash drains; alpha from May proxy-driven volatility and Q2 catalysts.

27 high priority23 medium50 total filings

March 26, 2026·daily

S&P 500 Energy Sector SEC Filings — March 26, 2026

Across 12 SEC filings in the USA S&P 500 Energy intelligence stream (including midstream and LNG players like Targa Resources, Williams Companies, and Golar LNG), overarching themes include robust revenue growth in select reporters (e.g., Golar LNG +51% YoY, Galapagos NV +304% YoY) offset by rising costs, impairments, and margin pressures, with Williams Sonoma net earnings -3.3% YoY despite +1.2% revenue. Governance activity dominates with multiple proxy statements and board changes, notably Williams Companies reducing board size post-Alan Armstrong's resignation for U.S. Senate role, signaling leadership transitions in energy midstream. Capital allocation shows shareholder returns via buybacks ($862M at Williams Sonoma) and dividends ($327M), alongside capital raises like Peapack-Gladstone's $50M preferred stock. Forward-looking catalysts cluster around April-May 2026 AGMs and events like Enhanced Games launch, amid mixed sentiment (5/12 mixed or negative). Portfolio-level trends reveal 3/5 financial reporters with YoY revenue acceleration (avg +119%) but operating challenges (e.g., Golar expenses +31%, Galapagos R&D +37%), implying selective growth opportunities in energy services/LNG versus broader cost headwinds. Market implications favor monitoring midstream governance stability and LNG revenue momentum for near-term positioning.

10 high priority2 medium12 total filings

March 26, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 26, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily FY2025 10-Ks, 8-Ks, and proxy statements), overarching themes include a wave of proxy filings signaling May 2026 annual meetings for governance votes, mixed FY2025 financials with average revenue declines of ~12% YoY in 15/20 reporting companies (e.g., Shoe Carnival -5.6%, VirTra -15%, Identiv -19%) offset by cost cuts and margin improvements in 8/15 (e.g., CV Sciences gross margin +340 bps to 49%), and selective growth outliers like Galapagos NV +304% revenues to €1.11B. Capital allocation leans positive with dividend hikes (Shoe Carnival +11% to $0.60, Oshkosh +11.8% to $0.57) and buybacks (Banc of California 8% shares repurchased), but dilution risks from warrant exercises (Wheeler REIT 12% new shares) and shelf registrations (Kyverna $300M). Leadership transitions (Vitesse CEO change, CNH directors not re-electing) and biotech catalysts (Kyverna BLA 1H2026) provide upside, while retail/consumer and SPACs show weakness amid macro pressures. Portfolio-level, financials/banks exhibit NIM expansion (Hoyne +86 bps to 3.24%, Farmers & Merchants +34 bps to 3.02%), contrasting tech/manufacturing declines. Implications: Near-term proxy-driven volatility low materiality; focus on turnaround plays and dividend growers for defensive positioning.

27 high priority23 medium50 total filings

March 26, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 26, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, gaming/entertainment proxies), overarching themes reveal mixed financial performance with revenue growth in 6/14 key operational reporters averaging +10% YoY (e.g., Ulta +9.7%, Laird +15%, SKYX +7%) offset by widespread margin compression averaging -120 bps (Laird -300 bps, Ulta -150 bps, Oxford ongoing pressures). Capital allocation leans shareholder-friendly with dividend hikes (Oxford to $0.70/share, First Bancorp declaration) and buybacks (Banc of California 8% shares repurchased), while M&A/integration (Laird/Navitas $38.5M) and debt optimization (Wolfspeed -43% notes redeemed, -13% debt) signal resilience. Proxies dominate (18/50 filings) clustering annual meetings in May 2026, highlighting governance catalysts amid neutral-to-positive sentiment. Portfolio-level trends show 4/10 consumer-facing firms guiding modest 2026 growth despite tariffs/commodity headwinds, with infra/funds (KKR +111% net ops) outperforming pure plays. Critical developments include Ulta's store expansion to 1,591 (+10%) and SKYX's gross margin to 30% (+100 bps), implying selective alpha in resilient retail/gaming vs. broader deterioration in legacy assets.

26 high priority24 medium50 total filings

March 26, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 26, 2026

Across 50 filings from the S&P 500 Healthcare stream and adjacent sectors, proxy statements dominate (e.g., Edwards Lifesciences, Centene, Alto Neuroscience) with neutral sentiment, setting up May 2026 annual meetings as key catalysts for director elections, auditor ratifications, and equity plan approvals. Financial results are mixed: small biotechs like Dare Bioscience (+10,429% YoY revenue from licenses) and STRATA Skin Sciences (-9% revenue but +49% operating loss improvement) show cost discipline narrowing losses despite revenue softness, while providers like Centene report challenging 2025 EPS ($2.08) but guide >$3.00 for 2026 (+40% YoY growth). Non-healthcare outliers like Corebridge Financial's $22B all-stock merger with Equitable (51/49 ownership split, $500M synergies by 2028, close YE2026) and Newmont's record 2025 FCF/$3B buybacks highlight capital returns, but healthcare trends emphasize R&D cuts (Dare -61% YoY) and positive pipeline catalysts (Artelo/Wave). Aggregate period trends: 7/12 reporting companies saw revenue declines averaging -10% YoY (e.g., CV Sciences -12%, STRATA -9%), but operating losses improved in 6/8 cases (avg +35% narrowing), signaling efficiency amid growth headwinds. Forward-looking optimism in biotech (e.g., Newsmax 13% rev growth FY26, though non-HC) contrasts with cash burn risks (Arcadia cash to $259K). Portfolio implication: Favor cost-cutters like Dare/CV Sciences for turnaround; monitor May proxies for governance shifts.

33 high priority17 medium50 total filings

March 25, 2026·daily

S&P 500 Technology Sector SEC Filings — March 25, 2026

Across 25 filings in the USA S&P 500 Technology intelligence stream (despite sector mix including non-tech), proxy statements dominate (12/25) signaling AGM season kickoff with May 2026 meetings, emphasizing governance enhancements like board refreshment at Century Communities and Cadence. Financial results show mixed trends: revenue growth in standouts like Adobe (+12% YoY to $6.4B subscription-driven) and Lafayette Square (+50% investment income to $84.7M), contrasted by declines in Dyadic (-12% YoY revenue) and Planet 13 (-11.2% FY revenue). Capital returns remain robust with $144M buybacks at Century Communities, $2.5B repurchases at Adobe, and $0.25 quarterly dividend at Dime Community. Leadership transitions emerge as a theme in tech-relevant names: Adobe CEO Shantanu Narayen stepping down (search underway), TXN SVP retirement, and Muzinich funds' C-suite overhaul. Period-over-period, 4/7 key financial filers posted YoY revenue growth (avg +17%), but margins mixed with Planet 13 improving to 38.6% yet EBITDA flipping to loss; non-tech outliers like Century Communities highlight operational efficiencies (costs -13k/home). Tech sector implications: Adobe's strength and Micron's debt tender signal balance sheet optimization amid AI/semiconductor cycles, positioning for H2 catalysts.

13 high priority12 medium25 total filings

March 25, 2026·daily

Nasdaq 100 Stocks SEC Filings — March 25, 2026

Across 20 NASDAQ-100 related SEC filings from March 25, 2026, key themes include robust capital returns via dividends and buybacks (e.g., Century Communities $178.4M dividends + $144M repurchases, Adobe $2.48B buybacks), mixed financial performance with standout growth in homebuilding (Century rev $4.1B) and software (Adobe +12% YoY rev to $6.4B) offset by biotech declines (Dyadic -12% rev, wider losses) and banking stress (TCBS NPAs +316% to 2.65%). Leadership transitions dominate tech and funds (Adobe CEO search, TXN SVP retirement, Muzinich dual entities CEO/CFO changes effective Apr 1), signaling potential continuity risks but no disagreements noted. Period-over-period trends show YoY revenue growth averaging +7% in highlighted firms (Adobe +12%, Century strong units), but asset/loan quality deterioration in banks (TCBS assets -3% YoY, deposits -2%). Capital allocation leans shareholder-friendly with steady dividends (Dime $0.25, CMC $0.20), while debt actions (Micron tenders, OneMeta $2.2M notes maturing Mar 26) and SPAC stasis (Axiom no combo) add liquidity nuances. Portfolio implications favor overweighting growth outperformers like Adobe/Century amid sector rotation from stressed small caps.

11 high priority9 medium20 total filings

March 25, 2026·daily

S&P 500 Financials Sector SEC Filings — March 25, 2026

Across 50 SEC filings from S&P 500 Financials and related entities dated March 25, 2026, overarching themes include resilient revenue growth in select tech-adjacent financial services (avg 16% YoY in Pure Storage, UiPath, Braze) offset by margin compression (avg -100bps in Rentokil, Braze, Spectral AI) and persistent SPAC challenges with high redemptions eroding trust balances (e.g., Concord -99.6%, byNordic -53%). Capital allocation leans shareholder-friendly with dividend hikes (Zedge +25% to $0.02/share), buybacks (News Corp $1B program, Chiba Bank ¥14.5B preferred repurchase), and M&A activity (Sandisk $1B Nanya stake at 15% discount, Thermon/CECO merger synergies). Mixed sentiment prevails (28/50 mixed/neutral), with positive signals from profitability turnarounds (UiPath $282M net income vs prior loss) and forward catalysts like AGMs (NOVAGOLD May 14), liquidations (Stratus $29.73-$37.69/share), and Phase 2 trials (Maze Therapeutics mid-2026). Portfolio-level trends show 12/20 revenue reporters growing >10% YoY but 8/15 loss-makers widening deficits amid high opEx (avg +20% in Pure, Braze). Key implications: Favor growth names with cash buffers (Chewy $860M cash, Energous $39.4M post-raise) over liquidity-strapped SPACs; monitor Q2 catalysts for alpha.

31 high priority19 medium50 total filings

March 25, 2026·daily

S&P 500 Consumer Staples Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, and related sectors amid mixed filings), overarching themes include modest revenue growth in select REITs and producers (avg +1-15% YoY in AFFO/revenues for Modiv/Global Self/Fresh Del Monte), robust M&A activity (e.g., Fresh Del Monte's $285M Del Monte assets acquisition), stable dividend declarations (Armour $0.24/share, Global Self $0.0725/qtr), and neutral compliance-heavy trust/SPAC reports dominating volume. Period-over-period trends show mixed results: AFFO/FFO growth (Modiv +15.1% YoY, Global Self +3.4%) offset by net income declines (Modiv -91.5%, Global Self -4%) and impairments, with Consumer Staples standouts like Fresh Del Monte and Hershey showing expansion via deals/proxies. Critical developments include positive merger synergies (Thermon/CECO), FDA priority review (Celcuity PDUFA Jul 17, 2026), and NYSE delisting risks (SelectQuote), implying sector resilience in branded foods amid macro pressures but vigilance on REIT-like exposures misaligned with staples. Portfolio-level patterns reveal 4/10 key filings with YoY revenue/NOI stability (+0.6-1.4%), dividend commitment signaling conviction, and upcoming catalysts in meetings/M&A closings driving near-term alpha.

30 high priority20 medium50 total filings

March 25, 2026·daily

S&P 500 Industrials Sector SEC Filings — March 25, 2026

Across the 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), sentiment is mixed with 14 positive, 16 mixed, and 20 neutral/bearish outcomes, highlighting revenue resilience in select industrials (Winnebago +6% QoQ, Generac $4.2B FY sales) amid broader challenges in adjacent biotech/pharma and financials. Key period-over-period trends include revenue growth averaging +12% YoY in growth outperformers (Pure Storage +16%, Local Bounti +27%, ECB Bancorp NII +29%), but persistent net losses in biotech (Kiora -$10.8M vs +$3.6M prior, Armata -$173M), margin pressures (Pure Storage opex +17-20%), and asset quality deterioration (Texas Community NPA +316%). Critical developments feature M&A momentum (Fresh Del Monte $285M acquisition, Merck/Terns $6.7B at 31% premium), dividend hikes signaling confidence (Zedge +25% to $0.02, Parke $0.18), and SPAC trust balances exceeding $230M (Aldel $243M, Range $232M). Capital allocation favors returns (3M $4.8B dividends/buybacks, Armour $0.24 monthly div), with forward catalysts clustered in May 2026 proxy meetings and Q2-Q3 pharma readouts. Portfolio-level patterns show industrials/transport outperforming (e.g., Winnebago profitable turnaround) versus biotech drags, implying selective rotation into revenue growers with strong balance sheets.

32 high priority18 medium50 total filings

March 25, 2026·daily

S&P 500 Energy Sector SEC Filings — March 25, 2026

Across the 7 filings in the USA S&P 500 Energy stream, dominant themes include neutral governance updates (board retirements at ONEOK, bylaws amendments at Chevron, proxy solicitations at Chesapeake Utilities) with low-to-moderate materiality, contrasted by mixed sentiment in non-core IPO registrations (AsiaPac AdTechinno, Texxon Holding) highlighting controlled company structures and growth funding needs. Kaanapali Land's 10-K reveals deteriorating financials with net loss widening to $3.7M (-236% YoY from $1.1M), revenues down 16% YoY to $1.6M, cash -32% to $15.8M, and operating cash use doubling to $5.9M, marking a clear underperformer. No insider trading activity reported across filings; capital allocation shows stable distributions at Kaanapali ($0.9M in 2025 vs $0.8M prior). Forward-looking catalysts cluster in Q2 2026: annual meetings (ONEOK May 20, CPK May 6), Texxon trial production April 2026, and pending IPOs. Portfolio-level trends limited by sparse metrics, but Kaanapali's margin improvements via 26% YoY op ex cut signal cost discipline amid revenue weakness. Overall neutral sector tone implies low volatility, with alpha in monitoring governance transitions and IPO dilutions risks.

5 high priority2 medium7 total filings

March 25, 2026·daily

Dow Jones 30 Stocks SEC Filings — March 25, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (period March 25, 2026), mixed financial results dominate with 12/20 10-K/10-Q filings showing revenue/AFFO growth (avg +12% YoY) offset by net income declines (avg -45% YoY) due to impairments and one-offs in REITs and industrials. Positive catalysts include raised guidance (e.g., Karman +53% revenue), M&A synergies (Thermon/CECO), and capital returns ($4.8B at 3M, $500M+ at Enact), while proxy season ramps up with 15+ AGMs in May 2026 featuring stock splits, say-on-pay, and director elections. REITs like Modiv (+15% AFFO) and Global Self Storage (+1.4% revenue, 93% occupancy) highlight operational resilience amid asset sales, but banks face nonperforming asset spikes (e.g., Texas Comm +316%). Overall sentiment skews mixed/neutral (28/50), with bullish outliers in growth sectors (space/defense, pharma) signaling portfolio rotation opportunities. Key implications: Favor companies with strong backlogs/guidance over those with impairments; monitor May catalysts for governance shifts and capital allocation updates.

29 high priority21 medium50 total filings

March 25, 2026·daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (despite diverse inclusions like SPACs, financials, and tech), proxy season dominates with 10+ DEF 14A/DEFA14A filings scheduling May 2026 annual meetings for director elections, auditor ratifications, and say-on-pay votes, signaling routine governance stability. Period-over-period trends show mixed revenue performance: growth in Cognyte (+14% YoY to $400M), Rentokil (+4% YoY to $6.9B), Jefferies (+27% YoY to $2B), but declines in Marchex (-6% FY to $45.4M), Marpai (-36% to $18.1M), Global Self Storage Q4 (-0.9% rev). Capital allocation leans positive with dividend hikes (Zedge +25% to $0.02, Omega Flex $0.34 quarterly) and buybacks (Jefferies auth +$250M), alongside acquisitions like Fresh Del Monte's $285M Del Monte assets deal. No widespread insider trading patterns, but board appointments (HBT Financial, Better Home) indicate strengthening governance. Forward-looking highlights include Marchex's positive 2026 guidance (Q1 Adj EBITDA +$0.5M, 10% run-rate rev growth) and SPAC timelines (24-month combo windows). Overall, sector shows resilient consumer plays amid volatility, with opportunities in M&A and dividends but risks from margin pressures (Rentokil op profit -9%) and delisting threats.

28 high priority22 medium50 total filings

March 25, 2026·daily

S&P 500 Healthcare Sector SEC Filings — March 25, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader market context), key themes include robust revenue growth in select non-healthcare adjacents like financials (Jefferies +27% YoY Q1 rev to $2B) and pet/health retail (Chewy +6.2% FY25 sales to $12.6B), contrasted by biotech losses widening amid R&D surges (ProMIS -214% R&D to $33M, net loss $39.7M; Precigen net loss to $429M on SG&A +70%). Capital allocation favors shareholders with dividends (Jefferies $0.40/share, HBT Financial board add) and buybacks (Jefferies $250M increase, News Corp $1B program). M&A activity signals consolidation (Danaher $9.9B Masimo acquisition, Lifeward Oratech amendment, Cintas UniFirst). Healthcare biotechs show pipeline progress (ProMIS Phase 1b enrollment complete, data Q3 2026; Precigen PAPZIMEOS J-code Apr 1 2026) despite cash burns. Board changes and proxy meetings cluster in May 2026, indicating governance refreshes. Overall, mixed sentiment (14/50 positive/mixed bullish drivers vs. biotech deterioration), with portfolio-level revenue growth avg +15% YoY in reporting firms but margin volatility (-150bps Chewy GAAP, +60bps gross). Actionable: Favor capex-efficient growers like Chewy (FCF +24% to $562M) over high-burn biotechs pending catalysts.

28 high priority22 medium50 total filings

March 24, 2026·daily

S&P 500 Technology Sector SEC Filings — March 24, 2026

Across the four filings in the USA S&P 500 Technology stream, dominant themes include deleveraging and operational restructuring at Ucommune International Ltd, uplisting ambitions at First Northern Community Bancorp, and routine organizational and funding disclosures from Capital One Multi Asset Execution Trust and Federal Home Loan Bank of San Francisco. Ucommune reported sharp YoY declines with revenue down 66% to RMB 26.1M and total assets -38% to RMB 202.5M, but offset by cash +44% to RMB 36.1M, liabilities -57% to RMB 74.2M, operating loss narrowed 12% to RMB 40.6M, and net loss improved 51% to RMB 39.3M following VIE deconsolidation. First Northern's Nasdaq uplisting application signals growth intent, while FHLB SF's $371.5M bond issuance reflects stable funding at 4.000%-4.520% coupons with maturities 2027-2031. Capital One Trust filing is benign with no financial metrics. Portfolio-level patterns show 1/4 filings with improving loss metrics amid declines (outlier Ucommune turnaround), no insider activity or capital allocation trends, and neutral/mixed sentiment overall. Market implications favor monitoring uplisting catalysts and deleveraging for relative outperformance versus stagnant peers.

2 high priority2 medium4 total filings

← All geographies